Study met Primary Endpoint of Non-Inferiority Versus Zoledronic Acid in Delaying Skeletal-Related Events

Longitudinal observational study reveals novel genetic markers of MM progression

The Multiple Myeloma Research Foundation’s CoMMpass study, a prospective, longitudinal observational study of 1,143 newly diagnosed, previously untreated multiple myeloma patients, revealed critical genetic markers that can better predict disease progression and identify patients at risk of transitioning to more aggressive forms of the disease.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Observational genetic study identifies unique types of MM

A 12-year observational study which aimed to sequence the genome, exome, and RNA in tumors from patients with multiple myeloma was able to define distinct subtypes of the disease, according to an international team of scientists led by researchers from the Translational Genomics Research Institute, part of City of Hope.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant.

August 09, 2024

Vol.50 No.32

Drugs & Targets

FDA approves Darzalex Faspro combination for MM

FDA has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomid, and dexamethasone (D-VRd) for induction and consolidation in patients with newly-diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.

August 02, 2024

Vol.50 No.31

Drugs & Targets

EMA accepts MAA for GSK’s Blenrep combinations for R/R MM

The European Medicines Agency has accepted the marketing authorization application for Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone (PomDex) as a treatment for relapsed or refractory multiple myeloma.

July 26, 2024

Vol.50 No.30

Clinical Roundup

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

The phase II MagnetisMM-3 study of Elrexfio (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.

June 21, 2024

Vol.50 No.25

Study met Primary Endpoint of Non-Inferiority Versus Zoledronic Acid in Delaying Skeletal-Related Events

YOU MAY BE INTERESTED IN

Longitudinal observational study reveals novel genetic markers of MM progression

Observational genetic study identifies unique types of MM

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

FDA approves Darzalex Faspro combination for MM

EMA accepts MAA for GSK’s Blenrep combinations for R/R MM

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login